What is inclusion body myositis?

Inclusion Body Myositis (IBM) is a rare, progressive muscle disease characterized by chronic muscle inflammation and weakness. It is the most common acquired muscle disease in adults over 50, affecting approximately 20,000 people in the United States.

Sporadic IBM (sIBM), the most common form, is NOT inherited — it occurs randomly. However, about 67% of patients carry a specific HLA gene combination that makes them genetically susceptible. Hereditary Inclusion Body Myopathies (hIBM) are a separate group of genetic muscle diseases.

Is there a cure for IBM?

As of 2026, there are no FDA-approved treatments specifically for IBM. The disease is notoriously resistant to corticosteroids and immunosuppressive drugs. Physical therapy and adaptive strategies are the mainstay of management. Active research is underway with promising clinical trials.

Does IBM qualify for disability benefits?

Yes. IBM is listed under Section 11.15 (Disorders of the Peripheral Nervous System) in the SSA Blue Book for Social Security Disability Insurance (SSDI). The IBM Functional Rating Scale can support your application.

What exercises are safe with IBM?

Walking, aquatic therapy, light resistance training, balance training, and hand/finger exercises are all recommended for IBM patients. Start slowly, build over 6-12 weeks, and consult with a physical therapist who understands myositis.

Why is IBM often misdiagnosed?

IBM is frequently misdiagnosed as polymyositis, normal aging, fibromyalgia, ALS, or sarcopenia. The average diagnostic delay is 5-10 years from symptom onset because IBM shares symptoms with more common conditions.

The Two Halves of IBM May Finally Fit Together: Faulty Muscle Proteins Triggering the Immune Attack

For decades, IBM researchers have argued over a basic question: does the disease start with inflammation attacking the muscle, or with the muscle degenerating on its own? A new peer-reviewed review published August 24, 2026 in Current Opinion in Neurology says the answer may be both — linked in a single chain reaction that starts inside the muscle cell itself.

What the Review Did

Dr. Naoki Suzuki and colleagues at Tohoku University Graduate School of Medicine in Sendai, Japan, systematically appraised every major IBM advance published between January 2025 and June 2026 — covering molecular causes, early diagnosis, disease-modifying therapies, and rehabilitation. Their conclusion is stated plainly in the title: IBM sits at the crossroads of cell-autonomous muscle degeneration and immune activation.

Finding 1: A Failing Protein May Turn the Immune System Against Muscle

The review highlights what it calls a pivotal advance. A protein called TDP-43 normally lives inside the cell nucleus, where it helps keep genetic instructions tidy — making sure muscle cells build their proteins correctly. In IBM muscle, TDP-43 drains out of the nucleus.

When that happens, the cell starts reading stretches of genetic code it should skip — called cryptic exons. The result is faulty protein fragments the immune system has never seen before. These fragments, called neoantigens, act like red flags: killer immune cells known as CD8-positive T cells recognize them as foreign and attack the muscle fiber carrying them.

In plain language: the muscle first makes a mistake, and the immune system then punishes it. Degeneration and inflammation are not rival theories — one triggers the other.

Finding 2: Leaking Mitochondria Sound the Alarm Even Earlier

A second chain reaction starts in the mitochondria — the tiny power plants inside muscle cells that make energy. Readers of this blog will remember the Mayo Clinic study we covered in August showing widespread mitochondrial failure in IBM muscle.

The review pulls that thread further: when mitochondria are damaged, fragments of their DNA leak into the main body of the cell. The cell mistakes this stray DNA for an invader and trips an ancient alarm system called cGAS-STING, part of the innate immune system. Crucially, this alarm fires before T cells even arrive — meaning inflammation is switched on from inside the muscle at a very early stage.

Finding 3: The Muscle Tries to Fight Back

There is also a hopeful subplot. The review points to a natural defense system called the NORAD-Pumilio axis — a pair of molecules that help cells cope with DNA damage. A study published in April 2026 found this system ramps up as IBM gets more severe, as if the muscle is trying to compensate and slow the disease down.

Researchers proved the point in mice bred to model hereditary IBM: animals with extra NORAD fared better, while animals with none fared worse. It is early evidence that boosting the cell’s own cleanup and repair machinery could one day become a treatment strategy.

What About Treatment?

On the clinical side, the review notes the preliminary signal from Abcuro’s Phase 2/3 MUSCLE trial of ulviprubart — the anti-KLRG1 antibody we covered in August — which suggested about 50% slowing of functional decline in people with mild-to-moderate IBM. The authors stress this is pending full peer-reviewed publication, so it should be read as encouraging but not yet proven.

The review also surveys emerging early-diagnostic tools and advanced rehabilitation, arguing the future of IBM care will be personalized: catch the disease earlier, match the right targeted drug to the right stage, and pair it with expert physical and swallowing therapy.

What This Means for IBM Patients

This review does not change treatment today — there is still no approved drug that slows IBM. But it changes the story researchers tell about your disease, and stories shape where money and trials go next.

If the immune attack is triggered by faulty proteins and leaking mitochondria inside the muscle, then future trials will likely need to do two things at once: calm the immune system and protect the muscle machinery. It also reinforces the message behind Abcuro’s planned new trial in earlier-stage disease — intervening before the chain reaction is entrenched may be the best chance of showing a benefit.

For patients, the practical takeaway stays the same for now: stay active with a therapist-guided program, get swallowing checked early, and consider following or joining observational studies and trials through your neurologist.

Where to Learn More

The review is technical but the abstract is readable and free on PubMed. If your clinician wants the full paper, it appears in the October 2026 issue of Current Opinion in Neurology, volume 39, pages 461-467.

Source

• Suzuki N, Izumi R, Ikeda K. "Paradigm shift in the pathomechanisms and treatment of inclusion body myositis: at the crossroads of cell-autonomous muscle degeneration and immune activation." Current Opinion in Neurology. 2026 Aug 24 (Oct issue 39(5):461-467). doi: 10.1097/WCO.0000000000001511. PMID: 42615630. https://pubmed.ncbi.nlm.nih.gov/42615630/